LG Life Sciences and Gilead to develop novel drug candidate caspase inhibitor

LG Life Sciences says that it signed with Gilead Sciences, Inc. of the United States an exclusive license agreement focused on the development of caspase inhibitors for the treatment of fibrotic diseases. The agreement grants Gilead commercialization rights to LG' caspase inhibitors, including LB84451, LG's lead compound.

LB84451 is an oral, once-daily pan-caspase inhibitor that demonstrate...